603998 方盛制药
交易中 09-15 10:06:46
资讯
新帖
简况
方盛制药:9月10日接受机构调研,华源证券、南方基金等多家机构参与
证券之星 · 09-14 18:08
方盛制药:9月10日接受机构调研,华源证券、南方基金等多家机构参与
方盛制药(603998)披露2026年半年度权益分派实施公告,9月7日股价上涨1.11%
证券之星 · 09-07
方盛制药(603998)披露2026年半年度权益分派实施公告,9月7日股价上涨1.11%
每周股票复盘:方盛制药(603998)H1净利增16.79%
证券之星 · 09-06
每周股票复盘:方盛制药(603998)H1净利增16.79%
方盛制药:公司将于8月31日召开2026年半年度业绩暨现金分红说明会
证券日报网 · 08-31
方盛制药:公司将于8月31日召开2026年半年度业绩暨现金分红说明会
方盛制药(603998)披露2026年半年度报告,8月31日股价上涨4.38%
证券之星 · 08-31
方盛制药(603998)披露2026年半年度报告,8月31日股价上涨4.38%
股市必读:方盛制药中报 - 第二季度单季净利润同比增长34.93%
证券之星 · 08-31
股市必读:方盛制药中报 - 第二季度单季净利润同比增长34.93%
方盛制药(603998)2026年中报简析:营收净利润同比双双增长,盈利能力上升
证券之星 · 08-30
方盛制药(603998)2026年中报简析:营收净利润同比双双增长,盈利能力上升
每周股票复盘:方盛制药(603998)Q2净利同比增34.93%
证券之星 · 08-30
每周股票复盘:方盛制药(603998)Q2净利同比增34.93%
图解方盛制药中报:第二季度单季净利润同比增长34.93%
证券之星 · 08-29
图解方盛制药中报:第二季度单季净利润同比增长34.93%
股市必读:方盛制药新发布《方盛制药关于公司董事、副总经理辞职的公告》
证券之星 · 08-28
股市必读:方盛制药新发布《方盛制药关于公司董事、副总经理辞职的公告》
方盛制药(603998)披露关于强力枇杷露药品上市许可转让协议终止的进展公告,8月26日股价上涨0.69%
证券之星 · 08-26
方盛制药(603998)披露关于强力枇杷露药品上市许可转让协议终止的进展公告,8月26日股价上涨0.69%
每周股票复盘:方盛制药(603998)将召开2026年半年度业绩说明会
证券之星 · 08-23
每周股票复盘:方盛制药(603998)将召开2026年半年度业绩说明会
方盛制药(603998)披露2026年半年度业绩暨现金分红说明会公告,8月20日股价上涨2.86%
证券之星 · 08-20
方盛制药(603998)披露2026年半年度业绩暨现金分红说明会公告,8月20日股价上涨2.86%
股市必读:方盛制药(603998)8月14日披露最新机构调研信息
证券之星 · 08-17
股市必读:方盛制药(603998)8月14日披露最新机构调研信息
异动快报:方盛制药(603998)8月13日13点43分触及涨停板
证券之星 · 08-13
异动快报:方盛制药(603998)8月13日13点43分触及涨停板
方盛制药:三花接骨散等促进骨愈合
证券之星 · 08-06
方盛制药:三花接骨散等促进骨愈合
股市必读:方盛制药新发布《方盛制药关于公司产品拟中选第十二批国家组织药品集中带量采购的公告》
证券之星 · 08-05
股市必读:方盛制药新发布《方盛制药关于公司产品拟中选第十二批国家组织药品集中带量采购的公告》
方盛制药(603998)披露公司产品拟中选第十二批国家组织药品集中带量采购,8月3日股价上涨1.06%
证券之星 · 08-03
方盛制药(603998)披露公司产品拟中选第十二批国家组织药品集中带量采购,8月3日股价上涨1.06%
方盛制药(603998)披露关于签订项目回购协议的进展公告,7月28日股价下跌0.11%
证券之星 · 07-28
方盛制药(603998)披露关于签订项目回购协议的进展公告,7月28日股价下跌0.11%
方盛制药(603998)披露拟退出并购基金暨关联交易议案,7月15日股价上涨2.94%
证券之星 · 07-15
方盛制药(603998)披露拟退出并购基金暨关联交易议案,7月15日股价上涨2.94%
加载更多
公司概况
公司名称:
湖南方盛制药股份有限公司
所属行业:
医药制造业
上市日期:
2014-12-05
主营业务:
湖南方盛制药股份有限公司的主营业务是药品的研发、生产与销售。公司的主要产品是养血祛风止痛颗粒、玄七健骨片、小儿荆杏止咳颗粒、依折麦布片、藤黄健骨片、强力枇杷膏(蜜炼)、血塞通分散片、赖氨酸维B12颗粒、头孢克肟片、蒲地蓝消炎片、金英胶囊、龙血竭散、舒尔经胶囊。公司拥有国家火炬计划重点高新技术企业、国家企业技术中心、国家技术创新示范企业、国家博士后科研工作站等国家级创新资质,先后获评国家级守合同重信用企业、湖南省省长质量奖等多项重要荣誉。
发行价格:
14.85
{"stockData":{"symbol":"603998","market":"SH","secType":"STK","nameCN":"方盛制药","latestPrice":10.29,"timestamp":1789438006000,"preClose":10.41,"halted":0,"volume":1779700,"delay":0,"changeRate":-0.0115,"floatShares":438999999,"shares":438999999,"eps":0.7626,"marketStatus":"交易中","change":-0.12,"latestTime":"09-15 10:06:46","open":10.45,"high":10.45,"low":10.26,"amount":18365600,"amplitude":0.0183,"askPrice":10.29,"askSize":64,"bidPrice":10.28,"bidSize":44,"shortable":0,"etf":0,"ttmEps":0.7626,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1789443000000},"marketStatusCode":2,"adr":0,"adjPreClose":10.41,"symbolType":"stock","openAndCloseTimeList":[[1789435800000,1789443000000],[1789448400000,1789455600000]],"highLimit":11.45,"lowLimit":9.37,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":439081360,"isCdr":false,"pbRate":2.57,"roa":"--","peRate":13.493312,"roe":"11.33%","epsLYR":0.7,"committee":0.301823,"marketValue":4518000000,"turnoverRate":0.0041,"status":1,"floatMarketCap":4518000000},"requestUrl":"/m/hq/s/603998","defaultTab":"news","newsList":[{"id":"2667657349","title":"方盛制药:9月10日接受机构调研,华源证券、南方基金等多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2667657349","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667657349?lang=zh_cn&edition=full","pubTime":"2026-09-14 18:08","pubTimestamp":1789380486,"startTime":"0","endTime":"0","summary":"证券之星消息,2026年9月14日方盛制药发布公告称公司于2026年9月10日接受机构调研,华源证券、南方基金、浩友投资参与。随着集采药品“三进”政策持续推进,产品院外渠道覆盖有望进一步扩大,为存量品种持续释放市场潜力创造有利条件。2026年6月,香港方盛堂已取得香港卫生署颁发的《中成药制造商牌照》,正式成为香港持牌中成药制造商。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091400024640.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","603998","161027","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665311705","title":"方盛制药(603998)披露2026年半年度权益分派实施公告,9月7日股价上涨1.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2665311705","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665311705?lang=zh_cn&edition=full","pubTime":"2026-09-07 17:45","pubTimestamp":1788774310,"startTime":"0","endTime":"0","summary":"截至2026年9月7日收盘,方盛制药报收于10.92元,较前一交易日上涨1.11%,最新总市值为47.95亿元。该股当日开盘10.75元,最高11.0元,最低10.75元,成交额达1.03亿元,换手率为2.15%。方盛制药于近日披露《2026年半年度权益分派实施公告》。股权登记日为2026年9月10日,除权(息)日与现金红利发放日均为2026年9月11日。分配对象为截至股权登记日在中国证券登记结算有限责任公司上海分公司登记在册的全体股东。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090700023042.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","603998","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665365958","title":"每周股票复盘:方盛制药(603998)H1净利增16.79%","url":"https://stock-news.laohu8.com/highlight/detail?id=2665365958","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665365958?lang=zh_cn&edition=full","pubTime":"2026-09-06 01:51","pubTimestamp":1788630670,"startTime":"0","endTime":"0","summary":"截至2026年9月4日收盘,方盛制药报收于10.8元,较上周的10.5元上涨2.86%。本周,方盛制药8月31日盘中最高价报11.39元。9月4日盘中最低价报10.74元。方盛制药当前最新总市值47.42亿元,在中药板块市值排名44/66,在两市A股市值排名3332/5214。主营业务方面,心脑血管用药收入同比增长50.01%,骨骼肌肉系统用药收入同比增长10.80%。公司2026年半年度拟每股派现0.20元(含税),分红金额预计达87,816,272元,占归母净利润的44.43%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090600000403.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","603998","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663100480","title":"方盛制药:公司将于8月31日召开2026年半年度业绩暨现金分红说明会","url":"https://stock-news.laohu8.com/highlight/detail?id=2663100480","media":"证券日报网","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663100480?lang=zh_cn&edition=full","pubTime":"2026-08-31 22:01","pubTimestamp":1788184860,"startTime":"0","endTime":"0","summary":"证券日报网讯8月31日,方盛制药发布公告称,公司计划于2026年8月31日09:00—10:00举行2026年半年度业绩暨现金分红说明会。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-08-31/doc-iniqfqsm7146388.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-08-31/doc-iniqfqsm7146388.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4588","BK0060","BK0239","603998","VIG","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663726580","title":"方盛制药(603998)披露2026年半年度报告,8月31日股价上涨4.38%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663726580","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663726580?lang=zh_cn&edition=full","pubTime":"2026-08-31 18:39","pubTimestamp":1788172756,"startTime":"0","endTime":"0","summary":"截至2026年8月31日收盘,方盛制药报收于10.96元,较前一交易日上涨4.38%,最新总市值为48.12亿元。该股当日开盘11.16元,最高11.39元,最低10.87元,成交额达4.17亿元,换手率为8.58%。近日,方盛制药披露《2026年半年度报告》。公告显示,公司总资产为3,091,500,784.95元,较上年度末增长1.17%;归属于上市公司股东的净资产为1,777,104,655.53元,同比增长3.82%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083100029466.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603998","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663042400","title":"股市必读:方盛制药中报 - 第二季度单季净利润同比增长34.93%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663042400","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663042400?lang=zh_cn&edition=full","pubTime":"2026-08-31 02:53","pubTimestamp":1788115988,"startTime":"0","endTime":"0","summary":"截至2026年8月28日收盘,方盛制药报收于10.5元,上涨1.74%,换手率3.63%,成交量15.94万手,成交额1.67亿元。业绩披露要点财务报告2026年上半年度公司主营收入9.58亿元,同比上升14.8%;归母净利润1.98亿元,同比上升16.79%;扣非净利润1.74亿元,同比上升23.07%。其中第二季度单季度主营收入4.95亿元,同比上升18.94%;单季度归母净利润1.09亿元,同比上升34.93%;单季度扣非净利润8827.36万元,同比上升24.96%;负债率39.57%,投资收益2185.71万元,财务费用350.84万元,毛利率75.81%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083100000850.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603998"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663048460","title":"方盛制药(603998)2026年中报简析:营收净利润同比双双增长,盈利能力上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2663048460","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663048460?lang=zh_cn&edition=full","pubTime":"2026-08-30 06:14","pubTimestamp":1788041641,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理,近期方盛制药发布2026年中报。截至本报告期末,公司营业总收入9.58亿元,同比上升14.8%,归母净利润1.98亿元,同比上升16.79%。按单季度数据看,第二季度营业总收入4.95亿元,同比上升18.94%,第二季度归母净利润1.09亿元,同比上升34.93%。本报告期方盛制药盈利能力上升,毛利率同比增幅7.84%,净利率同比增幅4.1%。本文数据来源于方盛制药2026年中报,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083000002262.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603998"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663109160","title":"每周股票复盘:方盛制药(603998)Q2净利同比增34.93%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663109160","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663109160?lang=zh_cn&edition=full","pubTime":"2026-08-30 02:50","pubTimestamp":1788029418,"startTime":"0","endTime":"0","summary":"截至2026年8月28日收盘,方盛制药报收于10.5元,较上周的9.93元上涨5.74%。股本股东变化截至2026年6月30日,方盛制药股东户数为2.37万户,较3月31日减少1317户,减幅5.27%。业绩披露要点方盛制药2026年中报显示,上半年主营收入9.58亿元,同比上升14.8%;归母净利润1.98亿元,同比上升16.79%;扣非净利润1.74亿元,同比上升23.07%。其中第二季度单季主营收入4.95亿元,同比上升18.94%;单季归母净利润1.09亿元,同比上升34.93%;单季扣非净利润8827.36万元,同比上升24.96%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083000000937.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603998","BK0239","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663018366","title":"图解方盛制药中报:第二季度单季净利润同比增长34.93%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663018366","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663018366?lang=zh_cn&edition=full","pubTime":"2026-08-29 01:36","pubTimestamp":1787938580,"startTime":"0","endTime":"0","summary":"证券之星消息,方盛制药2026年中报显示,上半年度公司主营收入9.58亿元,同比上升14.8%;归母净利润1.98亿元,同比上升16.79%;扣非净利润1.74亿元,同比上升23.07%;其中2026年第二季度,公司单季度主营收入4.95亿元,同比上升18.94%;单季度归母净利润1.09亿元,同比上升34.93%;单季度扣非净利润8827.36万元,同比上升24.96%;负债率39.57%,投资收益2185.71万元,财务费用350.84万元,毛利率75.81%。财报数据概要请见下图:本文数据来源于方盛制药2026年中报,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082900004629.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603998"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662035799","title":"股市必读:方盛制药新发布《方盛制药关于公司董事、副总经理辞职的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2662035799","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662035799?lang=zh_cn&edition=full","pubTime":"2026-08-28 05:12","pubTimestamp":1787865136,"startTime":"0","endTime":"0","summary":"公司公告汇总方盛制药关于公司董事、副总经理辞职的公告湖南方盛制药股份有限公司董事会于2026年8月26日收到公司董事、副总经理陈波递交的书面辞职报告。陈波因个人原因,申请辞去公司董事、副总经理及董事会薪酬与考核委员会委员职务,辞职后不再担任公司任何职务。其辞职报告自送达董事会之日起生效。陈波持有公司237,500股股票,不存在未履行完毕的公开承诺,已做好工作交接。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082800009612.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","603998","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662792731","title":"方盛制药(603998)披露关于强力枇杷露药品上市许可转让协议终止的进展公告,8月26日股价上涨0.69%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662792731","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662792731?lang=zh_cn&edition=full","pubTime":"2026-08-26 17:55","pubTimestamp":1787738145,"startTime":"0","endTime":"0","summary":"截至2026年8月26日收盘,方盛制药报收于10.17元,较前一交易日上涨0.69%,最新总市值为44.65亿元。方盛制药于近日披露《关于公司受让药品生产技术的进展公告》。公告显示,2022年12月14日,方盛制药与回春堂药业签订协议,以230万元受让“强力枇杷露”药品品种所有权;2023年3月,该品种所有权转让至全资子公司滕王阁药业;2025年7月21日,公司及滕王阁药业与康普药业签订协议,拟将该品种以不低于成本价的价格转让给康普药业。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082600040857.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","603998","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661211141","title":"每周股票复盘:方盛制药(603998)将召开2026年半年度业绩说明会","url":"https://stock-news.laohu8.com/highlight/detail?id=2661211141","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661211141?lang=zh_cn&edition=full","pubTime":"2026-08-23 02:07","pubTimestamp":1787422031,"startTime":"0","endTime":"0","summary":"截至2026年8月21日收盘,方盛制药报收于9.93元,较上周的10.78元下跌7.88%。本周关注点公司公告汇总:方盛制药将于2026年8月31日召开2026年半年度业绩暨现金分红说明会。公司公告汇总方盛制药关于召开2026年半年度业绩暨现金分红说明会的公告湖南方盛制药股份有限公司将于2026年8月31日09:00-10:00通过上证路演中心网络互动方式召开2026年半年度业绩暨现金分红说明会,介绍公司2026年半年度经营成果、财务状况,并回答投资者提问。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082300000345.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0239","603998"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660380882","title":"方盛制药(603998)披露2026年半年度业绩暨现金分红说明会公告,8月20日股价上涨2.86%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660380882","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660380882?lang=zh_cn&edition=full","pubTime":"2026-08-20 22:41","pubTimestamp":1787236873,"startTime":"0","endTime":"0","summary":"截至2026年8月20日收盘,方盛制药报收于10.43元,较前一交易日上涨2.86%,最新总市值为45.8亿元。近日,方盛制药发布《关于召开2026年半年度业绩暨现金分红说明会的公告》。公告显示,公司将于2026年8月31日09:00-10:00通过上证路演中心网络互动方式召开说明会,介绍公司2026年半年度经营成果、财务状况,并回答投资者提问。投资者可于2026年8月24日至8月28日16:00前通过上证路演中心网站或公司邮箱提交问题。说明会结束后可通过上证路演中心查看会议情况。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082000045795.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0239","603998"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660177089","title":"股市必读:方盛制药(603998)8月14日披露最新机构调研信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2660177089","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660177089?lang=zh_cn&edition=full","pubTime":"2026-08-17 01:02","pubTimestamp":1786899737,"startTime":"0","endTime":"0","summary":"截至2026年8月14日收盘,方盛制药报收于10.78元,上涨0.09%,换手率13.23%,成交量58.1万手,成交额6.3亿元。交易信息汇总资金流向8月14日主力资金净流入2397.45万元,占总成交额3.81%;游资资金净流入3609.35万元,占总成交额5.73%;散户资金净流出6006.8万元,占总成交额9.54%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081700000388.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603998","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659135369","title":"异动快报:方盛制药(603998)8月13日13点43分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2659135369","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659135369?lang=zh_cn&edition=full","pubTime":"2026-08-13 13:50","pubTimestamp":1786600239,"startTime":"0","endTime":"0","summary":"证券之星8月13日盘中消息,13点43分方盛制药(603998)触及涨停板。其所属行业中药目前上涨。领涨股为陇神戎发。该股为创新药,医药,中药概念热股,当日创新药概念上涨3.54%,医药概念上涨2.63%,中药概念上涨2.48%。8月12日的资金流向数据方面,主力资金净流入264.06万元,占总成交额3.51%,游资资金净流出261.37万元,占总成交额3.47%,散户资金净流出2.69万元,占总成交额0.04%。近5日资金流向一览见下表:方盛制药主要指标及行业内排名如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081300019298.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603998","BK0239","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657683164","title":"方盛制药:三花接骨散等促进骨愈合","url":"https://stock-news.laohu8.com/highlight/detail?id=2657683164","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657683164?lang=zh_cn&edition=full","pubTime":"2026-08-06 15:33","pubTimestamp":1786001613,"startTime":"0","endTime":"0","summary":"证券之星消息,方盛制药08月06日在投资者关系平台上答复投资者关心的问题。请问公司在售药品里,有无对应骨伤修复、外伤止血、呼吸道炎症治疗的相关产品?是否可以用于洪涝灾害伤员救治?感谢您的关注,敬请注意投资风险。本文数据来源于上海证券交易所e互动,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080600020513.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603998","BK0239","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657568723","title":"股市必读:方盛制药新发布《方盛制药关于公司产品拟中选第十二批国家组织药品集中带量采购的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2657568723","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657568723?lang=zh_cn&edition=full","pubTime":"2026-08-05 01:22","pubTimestamp":1785864132,"startTime":"0","endTime":"0","summary":"截至2026年8月4日收盘,方盛制药报收于9.54元,下跌0.21%,换手率1.52%,成交量6.66万手,成交额6387.27万元。公司公告汇总:公司产品吲哚布芬片及全资子公司产品比索洛尔氨氯地平片拟中选第十二批国家组织药品集中带量采购,采购周期至2029年12月31日。吲哚布芬片适用于缺血性心脑血管疾病等,比索洛尔氨氯地平片用于高血压替代治疗。采购周期至2029年12月31日,采购协议每年一签或一次性签约。拟中选结果尚在公示期,最终以国家联采办发布数据为准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080500001606.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0239","603998"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656377420","title":"方盛制药(603998)披露公司产品拟中选第十二批国家组织药品集中带量采购,8月3日股价上涨1.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2656377420","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656377420?lang=zh_cn&edition=full","pubTime":"2026-08-03 22:37","pubTimestamp":1785767834,"startTime":"0","endTime":"0","summary":"截至2026年8月3日收盘,方盛制药报收于9.56元,较前一交易日上涨1.06%,最新总市值为41.98亿元。公告显示,公司参加第十二批国家组织药品集中带量采购,产品吲哚布芬片及全资子公司广东方盛健盟药业有限公司产品比索洛尔氨氯地平片拟中选。吲哚布芬片适用于缺血性心脑血管疾病等,比索洛尔氨氯地平片用于高血压替代治疗。采购周期至2029年12月31日,采购协议每年一签或一次性签约。拟中选结果尚在公示期,最终以国家联采办发布数据为准。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080300037637.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","603998","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654883351","title":"方盛制药(603998)披露关于签订项目回购协议的进展公告,7月28日股价下跌0.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2654883351","media":"证券之星","labels":["buyback"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654883351?lang=zh_cn&edition=full","pubTime":"2026-07-28 22:25","pubTimestamp":1785248717,"startTime":"0","endTime":"0","summary":"截至2026年7月28日收盘,方盛制药报收于9.13元,较前一交易日下跌0.11%,最新总市值为40.09亿元。近日,方盛制药发布《关于签订项目回购协议的进展公告》。公告显示,2024年8月27日,公司与正帆建设、金帆建设、滕王阁药业、南昌经开控股签署《项目回购协议》,委托正帆建设代建南昌基地项目,预计回购价款不超过2亿元。目前公司及滕王阁药业已完成审批,其他方尚在履行审批程序。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072800039901.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603998","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651850461","title":"方盛制药(603998)披露拟退出并购基金暨关联交易议案,7月15日股价上涨2.94%","url":"https://stock-news.laohu8.com/highlight/detail?id=2651850461","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651850461?lang=zh_cn&edition=full","pubTime":"2026-07-15 22:16","pubTimestamp":1784124980,"startTime":"0","endTime":"0","summary":"截至2026年7月15日收盘,方盛制药报收于10.17元,较前一交易日上涨2.94%,最新总市值为44.65亿元。近日,方盛制药发布2026年第一次临时股东会决议公告。公告显示,公司于2026年7月15日召开2026年第一次临时股东会,审议通过了《关于公司拟退出并购基金暨关联交易的议案》。出席会议股东共240人,代表有表决权股份36,336,821股,占公司总股本的13.2855%。议案获同意票36,192,920股,占比99.6039%,反对和弃权票分别为79,001股和64,900股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071500044820.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603998","BK0239","BK0060"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1789438015237,"stockEarnings":[{"period":"1week","weight":-0.0284},{"period":"1month","weight":-0.0158},{"period":"3month","weight":0.111},{"period":"6month","weight":-0.0939},{"period":"1year","weight":-0.0144},{"period":"ytd","weight":-0.0293}],"compareEarnings":[{"period":"1week","weight":-0.012},{"period":"1month","weight":-0.0107},{"period":"3month","weight":-0.0505},{"period":"6month","weight":-0.0437},{"period":"1year","weight":0.0038},{"period":"ytd","weight":-0.021}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"湖南方盛制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"23656人(较上一季度减少5.27%)","perCapita":"18561股","listingDate":"2014-12-05","address":"湖南省长沙市岳麓区高新区麓松路789号","registeredCapital":"43908万元","survey":" 湖南方盛制药股份有限公司的主营业务是药品的研发、生产与销售。公司的主要产品是养血祛风止痛颗粒、玄七健骨片、小儿荆杏止咳颗粒、依折麦布片、藤黄健骨片、强力枇杷膏(蜜炼)、血塞通分散片、赖氨酸维B12颗粒、头孢克肟片、蒲地蓝消炎片、金英胶囊、龙血竭散、舒尔经胶囊。公司拥有国家火炬计划重点高新技术企业、国家企业技术中心、国家技术创新示范企业、国家博士后科研工作站等国家级创新资质,先后获评国家级守合同重信用企业、湖南省省长质量奖等多项重要荣誉。","listedPrice":14.85},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"方盛制药(603998)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供方盛制药(603998)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"方盛制药,603998,方盛制药股票,方盛制药股票老虎,方盛制药股票老虎国际,方盛制药行情,方盛制药股票行情,方盛制药股价,方盛制药股市,方盛制药股票价格,方盛制药股票交易,方盛制药股票购买,方盛制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"方盛制药(603998)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供方盛制药(603998)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}